Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

被引：3

作者：

Delforge, Michel ^{[1
]}

Patel, Krina K. ^{[2
]}

Eliason, Laurie ^{[3
]}

Dhanda, Devender ^{[3
]}

Shi, Ling ^{[4
]}

Guo, Shien ^{[4
]}

Marshall, Thomas S. ^{[3
]}

Arnulf, Bertrand ^{[5
]}

Cavo, Michele ^{[6
]}

Nooka, Ajay K. ^{[7
]}

Manier, Salomon ^{[8
]}

Callander, Natalie S. ^{[9
]}

Giralt, Sergio A. ^{[10
]}

Einsele, Hermann ^{[11
]}

Ailawadhi, Sikander ^{[12
]}

Popa-McKiver, Mihaela ^{[3
]}

Cook, Mark ^{[13
]}

Otero, Paula Rodriguez ^{[14
]}

机构：

[1] Univ Hosp Leuven, Leuven, Belgium

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] Evidera, Bethesda, MD USA

[5] Univ Paris Cite, Hop St Louis, APHP, Paris, France

[6] Bologna Univ, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

[7] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[8] Ctr Hosp Univ Lille, Lille, France

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] Uniklinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[12] Mayo Clin, Jacksonville, FL 32224 USA

[13] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[14] Clin Univ Navarra, Pamplona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179152

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 47 条

[1] Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial
Delforge, Michel
Patel, Krina K.
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas S.
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie S.
Giralt, Sergio A.
Einsele, Hermann
Ailawadhi, Sikander
Popa-McKiver, Mihaela
Cook, Mark
Otero, Paula Rodriguez
BLOOD, 2023, 142
[2] Idecabtagene Vicleucel (ide-cel) versus Standard (std) Regimens in Patients (pts) with Triple-class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
Scheid, Christoph
Rodriguez-Otero, Paula
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie
Costa, Luciano J.
Vij, Ravi
Bahlis, Nizar J.
Moreau, Philippe
Solomon, Scott R.
Abrahamsen, Ingerid Weum
Baz, Rachid
Broijl, Annemiek
Chen, Christine
Jagannath, Sundar
Raje, Noopur
Delforge, Michel
Benjamin, Reuben
Pabst, Thomas
Iida, Shinsuke
Berdeja, Jesus
Truppel-Hartmann, Anna
Bhatnagar, Rashmi
Wu, Fan
Piasecki, Julia
Eliason, Laurie
Dhanda, Devender
Felten, Jasper
Caia, Andrea
Cook, Mark
Mckiver, Mihaela Popa
Giralt, Sergio
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 247 - 248
[3] Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
Rodriguez Otero, Paula
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina K.
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie S.
Costa, Luciano
Vij, Ravi
Bahlis, Nizar J.
Moreau, Philippe
Solomon, Scott R.
Abrahamsen, Ingerid Weum
Baz, Rachid
Broijl, Annemiek
Chen, Christine
Jagannath, Sundar
Raje, Noopur S.
Scheid, Christof
Delforge, Michel
Benjamin, Reuben
Pabst, Thomas
Iida, Shinsuke
Berdeja, Jesus G.
Truppel-Hartmann, Anna
Bhatnagar, Rashmi
Wu, Fan
Piasecki, Julia
Eliason, Laurie
Dhanda, Devender
Felten, Jasper
Caia, Andrea
Cook, Mark
Popa-McKiver, Mihaela
Giralt, Sergio A.
BLOOD, 2023, 142
[4] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
Giralt, Sergio
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie
Costa, Luciano J.
Vij, Ravi
Bahlis, Nizar J.
Moreau, Philippe
Solomon, Scott R.
Delforge, Michel
Berdeja, Jesus
Truppel-Hartmann, Anna
Yang, Zhihong
Favre-Kontula, Linda
Wu, Fan
Piasecki, Julia
Cook, Mark
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S527 - S528
[5] Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 a Phase 3 Randomized Controlled Trial (RCT)
Scheid, C.
Rodriguez, Otero P.
Ailawadhi, S.
Arnulf, B.
Patel, K.
Cavo, M.
Nooka, A. K.
Manier, S.
Callander, N.
Costa, L. J.
Vij, R.
Bahlis, N. J.
Moreau, P.
Solomon, S. R.
Delforge, M.
Berdeja, J.
Truppel-Hartmann, A.
Favre-Kontula, L.
Wu, F.
Piasecki, J.
Cook, M.
Giralt, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 79 - 80
[6] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
Patel, Krina
Rodriguez-Otero, Paula
Manier, Salomon
Baz, Rachid
Raab, Mark-Steffen
Cavo, Michele
Callander, Natalie
Costa, Luciano J.
Moreau, Phillippe
Solomon, Scott
Chen, Christine
Raje, Noopur
Scheid, Christoph
Delforge, Michel
Larsen, Jeremy
Pabst, Thomas
Suzuki, Kenshi
Truppel-Hartmann, Anna
Yang, Zhihong
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Giralt, Sergio
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S498
[7] Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy
Manier, Salomon
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Einsele, Hermann
Bahlis, Nizar
Munshi, Nikhil
Ailawadhi, Sikander
Arnulf, Bertrand
Nooka, Ajay
Vij, Ravi
Abrahamsen, Ingerid Weum
Broijl, Annemiek
Jagannath, Sundar
Benjamin, Reuben
Gergis, Usama
Sborov, Douglas
Iida, Shinsuke
Truppel-Hartmann, Anna
Yang, Zhihong
Bhatnagar, Rashmi
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Baz, Rachid
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S50 - S51
[8] Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis
Patel, Krina
Rodriguez-Otero, Paula
Manier, Salomon
Baz, Rachid
Raab, Marc
Cavo, Michele
Callander, Natalie
Costa, Luciano
Moreau, Philippe
Solomon, Scott
Chen, Christine
Raje, Noopur
Scheid, Christoph
Delforge, Michel
Larsen, Jeremy
Pabst, Thomas Mueller
Suzuki, Kenshi
Truppel-Hartmann, Anna
Yang, Zhihong
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Giralt, Sergio
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S56 - S57
[9] Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients
Patel, Krina K.
Rodriguez-Otero, Paula
Nooka, Ajay K.
Callander, Natalie S.
Solomon, Scott R.
Baz, Rachid
Sborov, Douglas W.
Gergis, Usama
Badros, Ashraf Z.
Giralt, Sergio A.
Pearse, Roger
Abonour, Rafat
Siegel, David S.
Larson, Sarah M.
Munshi, Nikhil C.
Truppel-Hartmann, Anna
Bhatnagar, Rashmi
Wu, Fan
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Mckiver, Mihaela Popa
Jagannath, Sundar
Ailawadhi, Sikander
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S551 - S552
[10] Patient reported outcomes in Triple Class Exposed, Relapsed/Refractory Multiple Myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): idecabtagene Vicleucel (ide-cel) versus standard regimens
Einsele, H.
Delforge, M.
Patel, K.
Eliason, L.
Dhanda, D.
Shi, L.
Guo, S.
Marshall, T.
Arnulf, B.
Cavo, M.
Nooka, A.
Manier, S.
Callander, N.
Giralt, S.
Ailawadhi, S.
McKiver, Popa M.
Cook, M.
Rodriguez Otero, P.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 83 - 83

← 1 2 3 4 5 →